Abivax S.A.

NASDAQ:ABVX

Biotechnology

Healthcare
$83.83 -0.61%

-$0.62 today

Market cap
$7.34B
Beta
-0.20
P/E (TTM)
-18.1
EPS (TTM)
-$4.83
52W Low $5.69High $148.83

Volume 1.19M

Average 1.59M

ABVX Weighted Avg Shares

Average number of basic shares outstanding during the period, used to calculate basic EPS.

Abivax S.A.NASDAQ: ABVX

Weighted Avg Shares · Q2 FY2026 · quarter ended Jun 2026

Weighted avg shares grows 25.6% year over year

Q2 FY2026 weighted avg shares of 79.65M shares rose 25.6% year over year. Over 3 fiscal years it compounded at +53.9% a year.

Context

  • Weighted avg shares increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterJun 2026
79.65M— QoQ
Last fiscal yearDec 2025
69.53M+10.3% YoY
Weighted Avg Shares past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+25.6%——
1 year+10.3%——
3-year CAGR+53.9%——
5-year CAGR——
10-year CAGR——

Weighted Avg Shares history

Shares · from the income statement

Latest · FY2025
69.53M EUR
Year-over-year change
+10.3%
4-year CAGR
+45.6%

Weighted Avg Shares vs competitors

How ABVX compares with its peers on the latest reported figures

  • ABVX's FY2025 weighted avg shares of 69.53M shares is the 8th highest of the 11 companies compared; the peer median is 111.65M shares.
  • Its year-over-year change of +10.3% is the 9th highest of 11, against a peer median of +24.9%.
  • Over three fiscal years its annual growth of +53.9% compares with a peer median of +28.4%.
ABVX Competitors Peer median
Weighted Avg Shares for ABVX and competitors
Company Period LTM YoY 3-year CAGR
IVAInventiva S.A.FY2025186.8M +259.4%+65.2%
ANNXAnnexon, Inc.LTM Mar 2026161.69M +14.3%+41.6%
SYRESpyre Therapeutics, Inc.LTM Sep 2026146.1M +155.9%+166.8%
ACRSAclaris Therapeutics, Inc.LTM Mar 2026124.17M +37.8%+23.4%
RCUSArcus Biosciences, Inc.LTM Jun 2026116.35M +20.1%+14.3%
NRIXNurix Therapeutics, Inc.LTM Aug 2026106.95M +29.6%+21.3%
SNDXSyndax Pharmaceuticals, Inc.LTM Mar 202686.55M +1.2%+12.5%
ABVXAbivax S.A.FY202569.53M +10.3%+53.9%
IMMXImmix Biopharma, Inc.LTM Mar 202634.62M +19.9%+33.4%
ANABAnaptysBio, Inc.LTM Mar 202628.59M -2.5%-0.4%
AVTXAvalo Therapeutics, Inc.LTM Mar 202615.86M +130.2%+599.3%
Peer median (excluding ABVX) 111.65M+24.9%+28.4%

Competitors are the stored peer set for ABVX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

EUR
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue00000
Cost of Revenue45.52M50.76M000
Gross Profit(45.52M)(50.76M)000
Gross Margin—————
Research & Development47.78M48.3M103.18M146.53M177.76M
Selling, General & Admin5.58M7.49M28.82M38.9M72.87M
Operating Expenses(4.12M)14.07M127.38M172.98M246.06M
Depreciation & Amortization302K485K707K1.1M1.07M
EBITDA(38.59M)(53.32M)(133.21M)(162.71M)(300.7M)
EBITDA Margin—————
Operating Income(41.4M)(64.84M)(127.38M)(172.98M)(246.06M)
Operating Margin—————
Interest Income002.77M8.96M5.75M
Interest Expense3.56M6.94M13.83M12.43M28.48M
Other Income / Expenses(1.05M)4.1M(20.36M)(3.26M)(84.2M)
Income Before Tax(42.45M)(60.74M)(147.74M)(176.24M)(330.25M)
Pre-Tax Margin—————
Income Tax Expense00005.85M
Net Income(42.45M)(60.74M)(147.74M)(176.24M)(336.1M)
Net Margin—————
EPS (Basic)(2.75)(3.18)(3.43)(2.80)(4.65)
EPS (Diluted)(2.75)(3.18)(3.43)(2.80)(4.65)
Weighted Avg Shares15.46M19.09M43.07M63.05M69.53M
Weighted Avg Shares (Diluted)15.46M19.09M43.07M63.05M69.53M

Abivax S.A.

NASDAQ:ABVX

Intrinsic Alpha fair value

Locked

Current Price

$83.83

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.